193 related articles for article (PubMed ID: 3470179)
1. New anthracycline analogs in advanced breast cancer.
Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
[TBL] [Abstract][Full Text] [Related]
2. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
Bastholt L; Dalmark M
Cancer Treat Rep; 1987 May; 71(5):451-4. PubMed ID: 3471329
[TBL] [Abstract][Full Text] [Related]
4. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Hurteloup P; Ganzina F
Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
[TBL] [Abstract][Full Text] [Related]
5. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
Brambilla C; Rossi A; Bonfante V; Ferrari L; Villani F; Crippa F; Bonadonna G
Cancer Treat Rep; 1986 Feb; 70(2):261-6. PubMed ID: 3456271
[TBL] [Abstract][Full Text] [Related]
7. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
9. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline analogs: the past, present, and future.
Weiss RB; Sarosy G; Clagett-Carr K; Russo M; Leyland-Jones B
Cancer Chemother Pharmacol; 1986; 18(3):185-97. PubMed ID: 2948729
[No Abstract] [Full Text] [Related]
11. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
12. [Adriamycin and its analogs].
Arcamone F
Tumori; 1984 Apr; 70(2):113-9. PubMed ID: 6587651
[TBL] [Abstract][Full Text] [Related]
13. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Young CW; Raymond V
Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
[No Abstract] [Full Text] [Related]
14. Phase II trial of idarubicin in patients with advanced lymphoma.
Gillies H; Liang R; Rogers H; Harper P; Parapia L; Cox G; Johnson S
Cancer Chemother Pharmacol; 1988; 21(3):261-4. PubMed ID: 3162850
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
Chisesi T; Capnist G; de Dominicis E; Dini E
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):681-4. PubMed ID: 3164269
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
Lambertenghi-Deliliers G; Colajori E; Annaloro C; Polli EE
Recenti Prog Med; 1985; 76(7-8):392-7. PubMed ID: 3906794
[No Abstract] [Full Text] [Related]
17. Phase II trial with oral idarubicin in advanced breast cancer.
Lopez M; Di Lauro L; Papaldo P; Lazzaro B; Ganzina F; Di Pietro N
Invest New Drugs; 1986; 4(1):39-42. PubMed ID: 3457780
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Stuart NS; Cullen MH; Priestman TJ; Blackledge GR; Tyrrell CJ
Cancer Chemother Pharmacol; 1988; 21(4):351-4. PubMed ID: 3163529
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
Smith DB; Howell A
Eur J Cancer Clin Oncol; 1987 Apr; 23(4):391-4. PubMed ID: 3475204
[TBL] [Abstract][Full Text] [Related]
20. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
